Clinical Coagulation, Malmö
21 – 30 of 630
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Infrastructural considerations of implementing gene therapy for hemophilia in the Nordic context
(
- Contribution to journal › Article
-
Mark
Considerations for shared decision management in previously untreated patients with hemophilia A or B
(
- Contribution to journal › Scientific review
-
Mark
Lung function, respiratory symptoms and incident venous thromboembolism during a 44-year follow-up
(
- Contribution to journal › Article
-
Mark
Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A : Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis
(
- Contribution to journal › Article
-
Mark
Dronedarone Versus Sotalol in Antiarrhythmic Drug-Naive Veterans With Atrial Fibrillation
(
- Contribution to journal › Article
-
Mark
Koagulationsfaktor XIII – inte bara ett kongenitalt blödningsproblem
(
- Contribution to journal › Scientific review
-
Mark
Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A
(
- Contribution to journal › Article
-
Mark
Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B : post hoc analysis of phase III trials using patient-reported outcomes
(
- Contribution to journal › Article
-
Mark
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction in development
(
- Contribution to journal › Debate/Note/Editorial